Shift’s E1V1.11 drug compound to treat Spinal Muscular Atrophy (SMA) granted Orphan Drug Status by FDA. Overland Park: The Food and Drug Administration (FDA) granted orphan drug designation for Shift Pharmaceutical’s lead drug compound to Read More …
CMT Research Foundation funds Shift to explore novel series of drugs created to control the expression of PMP22 gene Overland Park: In late January, the CMT Research Foundation (CMTRF) announced a partnership with Shift Pharmaceuticals Read More …
Overland Park: Shift Pharmaceuticals is pleased to announce the Company has been awarded a grant through the Congressional Directed Medical Research Program (CDMRP) to further the development of their initial drug candidate (E1v1.11) for the Read More …